Movement Alert｜Guardant Health Rises 5.26% in Regular Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines

Market Focus05-28

On May 28, Guardant Health rose 5.26% in regular trading, trading at $126.21 per share, with trading volume of $191 million.

On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an alternative option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.

This milestone follows closely after the FDA's recent approval of the company's Guardant360 Liquid CDx test as a companion diagnostic tool for non-small cell lung cancer and colorectal cancer therapies, which integrates genomic and epigenomic analysis through a single blood draw with 100x expanded genomic coverage.

Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics. The company offers products including Guardant360, Shield Test, and GuardantINFINITY, serving both clinical and biopharmaceutical customers globally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151225048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151225048","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Rises 5.26% in Regular Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines","media":"Market Focus","content":"<p><p>On May 28, Guardant Health rose 5.26% in regular trading, trading at $126.21 per share, with trading volume of $191 million.</p><p>On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an alternative option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.</p><p>This milestone follows closely after the FDA's recent approval of the company's Guardant360 Liquid CDx test as a companion diagnostic tool for non-small cell lung cancer and colorectal cancer therapies, which integrates genomic and epigenomic analysis through a single blood draw with 100x expanded genomic coverage.</p><p>Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics. The company offers products including Guardant360, Shield Test, and GuardantINFINITY, serving both clinical and biopharmaceutical customers globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Rises 5.26% in Regular Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Rises 5.26% in Regular Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 00:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, Guardant Health rose 5.26% in regular trading, trading at $126.21 per share, with trading volume of $191 million.</p><p>On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an alternative option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.</p><p>This milestone follows closely after the FDA's recent approval of the company's Guardant360 Liquid CDx test as a companion diagnostic tool for non-small cell lung cancer and colorectal cancer therapies, which integrates genomic and epigenomic analysis through a single blood draw with 100x expanded genomic coverage.</p><p>Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics. The company offers products including Guardant360, Shield Test, and GuardantINFINITY, serving both clinical and biopharmaceutical customers globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1151225048","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151225048","pubTimestamp":1779900477,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, Guardant Health rose 5.26% in regular trading, trading at $126.21 per share, with trading volume of $191 million.On the news front, the company announced that its Shield blood test has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动静提示|Guardant Health常规交易涨5.26%屏蔽血液检测纳入美国癌症协会筛查指南","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On May 28, Guardant Health rose 5.26% in regular trading, trading at $126.21 per share, with trading volume of $191 million.On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an alternative option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.This milestone follows closely after the FDA's recent approval of the company's Guardant360 Liquid CDx test as a companion diagnostic tool for non-small cell lung cancer and colorectal cancer therapies, which integrates genomic and epigenomic analysis through a single blood draw with 100x expanded genomic coverage.Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics. The company offers products including Guardant360, Shield Test, and GuardantINFINITY, serving both clinical and biopharmaceutical customers globally.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151225048","isCrawlerRequest":true}